TY - JOUR
T1 - Regulation of the Glycerol Transporter, Aquaporin-3, by Histone Deacetylase-3 and p53 in Keratinocytes
AU - Choudhary, Vivek
AU - Olala, Lawrence O.
AU - Kagha, Karen
AU - Pan, Zhi qiang
AU - Chen, Xunsheng
AU - Yang, Rong
AU - Cline, Abigail
AU - Helwa, Inas
AU - Marshall, Lauren
AU - Kaddour-Djebbar, Ismail
AU - McGee-Lawrence, Meghan E.
AU - Bollag, Wendy B.
N1 - Funding Information:
This work was supported in part by VA Merit Award #I01CX001357 to WBB and in part by an intramural Early Success Award from Augusta University to WBB. WBB was supported by a VA Research Career Scientist Award. The contents of this article do not represent the views of the Department of Veterans Affairs or the United States Government. Generation and maintenance of Hdac3 floxed mice was supported by the American Diabetes Association Award (1-16-JDF-062) to MML. Both KK and AC were supported by Alpha Omega Alpha Carolyn L. Kuckein Student Research fellowships. LM was a fellow of the Medical College of Georgia’s Medical Scholars Program.
Publisher Copyright:
© 2017 The Authors
PY - 2017/9
Y1 - 2017/9
N2 - Aquaporin- (AQP) 3, a water and glycerol channel, plays an important role in epidermal function, with studies showing its involvement in keratinocyte proliferation, differentiation, and migration and in epidermal wound healing and barrier repair. Increasing speculation about the use of histone deacetylase (HDAC) inhibitors to treat skin diseases led us to investigate HDAC's role in the regulation of AQP3. The broad-spectrum HDAC inhibitor suberoylanilide hydroxamic acid induced AQP3 mRNA and protein expression in a dose- and time-dependent manner in normal keratinocytes. The SAHA-induced increase in AQP3 levels resulted in enhanced [3H]glycerol uptake in normal but not in AQP3-knockout keratinocytes, confirming that the expressed AQP3 was functional. Use of HDAC inhibitors with different specificities limited our exploration of the responsible HDAC member to HDAC1, HDAC2, or HDAC3. Cre-recombinase–mediated knockdown and overexpression of HDAC3 suggested a role for HDAC3 in suppressing AQP3 expression basally. Further investigation implicated p53 as a transcription factor involved in regulating HDAC inhibitor-induced AQP3 expression. Thus, our study supports the regulation of AQP3 expression by HDAC3 and p53. Because suberoylanilide hydroxamic acid is already approved to treat cutaneous T-cell lymphoma, it could potentially be used as a therapy for skin diseases like psoriasis, where AQP3 is abnormally expressed.
AB - Aquaporin- (AQP) 3, a water and glycerol channel, plays an important role in epidermal function, with studies showing its involvement in keratinocyte proliferation, differentiation, and migration and in epidermal wound healing and barrier repair. Increasing speculation about the use of histone deacetylase (HDAC) inhibitors to treat skin diseases led us to investigate HDAC's role in the regulation of AQP3. The broad-spectrum HDAC inhibitor suberoylanilide hydroxamic acid induced AQP3 mRNA and protein expression in a dose- and time-dependent manner in normal keratinocytes. The SAHA-induced increase in AQP3 levels resulted in enhanced [3H]glycerol uptake in normal but not in AQP3-knockout keratinocytes, confirming that the expressed AQP3 was functional. Use of HDAC inhibitors with different specificities limited our exploration of the responsible HDAC member to HDAC1, HDAC2, or HDAC3. Cre-recombinase–mediated knockdown and overexpression of HDAC3 suggested a role for HDAC3 in suppressing AQP3 expression basally. Further investigation implicated p53 as a transcription factor involved in regulating HDAC inhibitor-induced AQP3 expression. Thus, our study supports the regulation of AQP3 expression by HDAC3 and p53. Because suberoylanilide hydroxamic acid is already approved to treat cutaneous T-cell lymphoma, it could potentially be used as a therapy for skin diseases like psoriasis, where AQP3 is abnormally expressed.
UR - http://www.scopus.com/inward/record.url?scp=85028320841&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85028320841&partnerID=8YFLogxK
U2 - 10.1016/j.jid.2017.04.031
DO - 10.1016/j.jid.2017.04.031
M3 - Article
C2 - 28526298
AN - SCOPUS:85028320841
SN - 0022-202X
VL - 137
SP - 1935
EP - 1944
JO - Journal of Investigative Dermatology
JF - Journal of Investigative Dermatology
IS - 9
ER -